Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?. (July 2017)

• Record Type: Journal Article
• Authors: Haass-Koffler, Carolina L; Akhlaghi, Fatemeh; Swift, Robert M; Leggio, Lorenzo
• Is Part Of: Journal of psychopharmacology. Volume 31:Number 7(2017)
• Page Start: 812
• Page End: 818
• Publication Date: 2017-07
• Subjects: Pharmacokinetics -- alcohol use disorder -- ethanol -- biobehavioral mechanisms -- human laboratory studies; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881116684338
• Languages: English
• ISSNs: 0269-8811

Abstract

Disulfiram was the first pharmacotherapy approved to treat alcohol use disorder in the 1950s. Disulfiram alters ethanol pharmacokinetics and causes uncomfortable reactions (e.g. headache, tachycardia, nausea, flushing and hypotension) when alcohol is consumed. Subsequently, a better understanding of the neurobiological pathways involved in alcohol use disorder led to the development of other medications (e.g. naltrexone and acamprosate). These neurobiological-based medications act on alcohol use disorder-related phenotypes including craving, stress, and/or withdrawal. The original approach to treat alcohol use disorder, by altering ethanol pharmacokinetics has been much less investigated. Recent research on ethanol pharmacokinetics has shed light on the mechanisms of action underlying alcohol use disorder and how some medications that alter ethanol pharmacokinetics may be helpful in treating alcohol use disorder. This review summarizes and discusses the complex pharmacokinetics of ethanol, and proposes that altering ethanol pharmacokinetics via novel pharmacological approaches may be a viable approach to treat alcohol use disorder.